Citadel Advisors’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

Citadel Advisors’s Portfolio OYST Stock Details OYST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-16,100	Closed	-$180K	–	16228
2022 Q4	$180K	Buy	+16,100	New	+$156K	﹤0.01%	10319
2022 Q1	–	Sell	-10,400	Closed	-$190K	–	15064
2021 Q4	$190K	Buy	+10,400	New	+$132K	﹤0.01%	11926

Other funds holding OYST

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's OYST Position: Q1 2023 in Review

Citadel Advisors sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q1 2023, closing a stake of 29,511 shares — an estimated $330K sold.

Citadel Advisors first reported a position in OYST in Q1 2020 and held it in 12 quarters. The position peaked at $8.13M in Q2 2020. 1 fund tracked by Wall St. Rank holds OYST as of Q1 2023.

Citadel Advisors reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 29,511 Oyster Point Pharma, Inc. Common Stock shares in Q1 2023, an estimated $330K.
Citadel Advisors first reported a position in Oyster Point Pharma, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
Citadel Advisors's Oyster Point Pharma, Inc. Common Stock position peaked at $8.13M in Q2 2020.
1 fund tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.